Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 15/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042609 | 1.00 | HSD17B3 (0.49) | HSD17B3NOTUMLMNAMEN1ALDH1A1 | |
| SCHEMBL5046193 | 0.91 | HSD17B3 (0.61) | HSD17B3NOTUMLMNA | |
| SCHEMBL5046195 | 0.91 | HSD17B3 (0.61) | HSD17B3NOTUMLMNA | |
| SCHEMBL5039020 | 0.87 | HSD17B3 (0.53) | HSD17B3NOTUM | |
| SCHEMBL5039019 | 0.87 | HSD17B3 (0.53) | HSD17B3NOTUM | |
| SCHEMBL5042517 | 0.86 | HSD17B3 (0.51) | HSD17B3NOTUM | |
| SCHEMBL5042515 | 0.86 | HSD17B3 (0.51) | HSD17B3NOTUM | |
| SCHEMBL15063049 | 0.81 | HSD17B3 (0.52) | HSD17B3NOTUMMEN1ALDH1A1CYP1A2 | |
| SCHEMBL15063050 | 0.81 | HSD17B3 (0.52) | HSD17B3NOTUMMEN1ALDH1A1CYP1A2 | |
| SCHEMBL5046261 | 0.80 | HSD17B3 (0.40) | HSD17B3NOTUMCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1725565-A2 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | Bristol-Myers Squibb Company (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005084295-A2 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | HSD17B3 1/4885NOTUM 907/4885LMNA 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.